Indoco Remedies Ltd
NSE:INDOCO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Indoco Remedies Ltd
NSE:INDOCO
|
IN |
|
MBB SE
XETRA:MBB
|
DE |
|
Kiplin Metals Inc
F:17G1
|
CA |
|
PhosAgro PAO
LSE:PHOR
|
RU |
Indoco Remedies Ltd
Indoco Remedies Ltd. engages in manufacturing and marketing of Formulations (Finished Dosage Forms) and active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2005-01-07. The firm is an integrated, research-oriented pharma company engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The firm's geographical segments include India and Outside India. The firm has nine domestic marketing divisions with a brand portfolio in various therapeutic segments, including Gastrointestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management and Gyneacology. The Company’s brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cal-Aid, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM and Methycal.
Indoco Remedies Ltd. engages in manufacturing and marketing of Formulations (Finished Dosage Forms) and active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2005-01-07. The firm is an integrated, research-oriented pharma company engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The firm's geographical segments include India and Outside India. The firm has nine domestic marketing divisions with a brand portfolio in various therapeutic segments, including Gastrointestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management and Gyneacology. The Company’s brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cal-Aid, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM and Methycal.
Growth in Exports: Indoco's Q3 performance was led by strong growth in exports, including notable gains in APIs and international formulations, particularly in Europe, the US, and emerging markets.
Domestic Business Flat: The domestic business was flat this quarter due to challenges in acute therapies, but secondary sales and prescription volumes remained stable.
Margins Improved: Consolidated EBITDA margin improved year-over-year, helped by better subsidiary performance and product mix, though quarter-over-quarter margins declined.
Cost Pressures: Consolidated other expenses remained high at INR 169 crores, including INR 8–9 crores of one-time and penalty costs, but management expects costs to normalize next quarter.
API and OTC Expansion: API business grew strongly, and the OTC/Oral Care segment continued to expand with new launches, with guidance for at least 30% growth in OTC next year.
Debt Reduction Plans: Debt stands at around INR 900 crores, with a clear repayment schedule and no major new capex planned; management targets a lower debt level by March 2027.
Regulatory Updates: US FDA remediation continues at Goa Plant II, with some supply and penalty impacts, but alternate supply strategies are in place; Patalganga API site received EIR with zero observations.
